MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, BTAI had $18,745K increase in cash & cash equivalents over the period. -$18,787K in free cash flow.

Cash Flow Overview

Change in Cash
$18,745K
Free Cash flow
-$18,787K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-30,911 -26,441
Depreciation
75 151
Accretion of debt discount and amortization of financing costs
440 743
Change in fair value of derivative liabilities
-12,541 7,222
Stock-based compensation expense
581 1,736
Payable-in-kind interest on credit agreement
1 5,433
Operating lease right-of-use assets
82 160
Accounts receivable
-17 -114
Inventory
-47 -173
Prepaid expenses, other current assets and other assets
480 -673
Accounts payable, accrued expenses, due to related parties, and other current liabilities
-1,084 45
Accrued interest
0 0
Operating lease liabilities
-96 -183
Net cash used in operating activities
-18,787 -24,618
Purchases of equipment and leasehold improvements
0 0
Net cash from investing activities
0 0
Proceeds from issuance of common stock and warrant
38,234 14,146
Offering costs for common stock and warrants issuance
686 806
Payment of employee tax obligations related to vesting restricted stock units
16 1
Net cash provided by financing activities
37,532 13,339
Net increase in cash, cash equivalents and restricted cash
18,745 -11,279
Cash and cash equivalents at beginning of period
29,854 -
Cash and cash equivalents at end of period
37,320 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics, Inc. (BTAI)